Has the epidemic of allergic contact dermatitis due to methylisothiazolinone reached its peak?

Br J Dermatol. 2017 Jul;177(1):276-278. doi: 10.1111/bjd.15016. Epub 2017 May 29.

Authors

Z C Venables¹, J F Bourke², D A Buckley³, F Campbell⁴, M M U Chowdhury⁵, S Abdul-Ghaffar⁶, C Green⁶, C R Holden⁷, J McFadden⁸, D Orton⁹, R A Sabroe⁷, J Sansom¹⁰, N M Stone¹¹, S H Wakelin¹², S M Wilkinson¹³, G A Johnston¹

Affiliations

¹ Leicester Royal Infirmary, Leicester, U.K.
² South Infirmary, Victoria University Hospital, Cork, Ireland.
³ Royal United Hospital, Bath, U.K.
⁴ The Queen Elizabeth University Hospital, Glasgow, U.K.
⁵ The Welsh Institute of Dermatology, Cardiff, U.K.
⁶ Ninewells Hospital and Medical School, Dundee, U.K.
⁷ Royal Hallamshire Hospital, Sheffield, U.K.
⁸ St John's Institute of Dermatology, London, U.K.
⁹ Hillingdon Hospital, Hillingdon, U.K.
¹⁰ Bristol Royal Infirmary, Bristol, U.K.
¹¹ Royal Gwent Hospital, Newport, U.K.
¹² St Mary's Hospital, London, U.K.
¹³ Chapel Allerton Hospital, Leeds, U.K.

PMID: 27579576
DOI: 10.1111/bjd.15016

No abstract available

Publication types

Letter
Multicenter Study

MeSH terms

Cosmetics / adverse effects
Dermatitis, Allergic Contact / epidemiology*
Drug Combinations
Epidemics*
Humans
Incidence
Ireland / epidemiology
Preservatives, Pharmaceutical / adverse effects*
Thiazoles / adverse effects*
United Kingdom / epidemiology

Substances

Cosmetics
Drug Combinations
Preservatives, Pharmaceutical
Thiazoles
2-methyl-4-isothiazolin-3-one
5-chloro-2-methyl-4-isothiazolin-3-one